Serosurvey of Hepatitis-B Surface Antigen in Afghan Refugees; the First Report from Qazvin, Iran

Gholamzadeh Khoei, Saeideh; Sadeghi, Hamid; Bakht, Mehdi; Rahimi, Sara; Mirshahabi, Hessam; Gheibi, Nematollah

doi:10.13183/rabms.6.3.194

Volume 6, Issue 3 (July 2020) Journal of Research in Applied and Basic Medical Sciences 2020, 6(3): 194-198 | Back to browse issues page

‎ 10.13183/rabms.6.3.194

Mendeley

Zotero

RefWorks

Gholamzadeh Khoei S, Sadeghi H, Bakht M, Rahimi S, Mirshahabi H, Gheibi N. Serosurvey of Hepatitis-B Surface Antigen in Afghan Refugees; the First Report from Qazvin, Iran. Journal of Research in Applied and Basic Medical Sciences 2020; 6 (3) :194-198
URL: http://ijrabms.umsu.ac.ir/article-1-133-en.html

Serosurvey of Hepatitis-B Surface Antigen in Afghan Refugees; the First Report from Qazvin, Iran

Saeideh Gholamzadeh Khoei

, Nematollah Gheibi ^*

Cellular and Molecular Research Center, Research Institute for Prevention of Non Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran , gheibi_n@yahoo.com

Abstract: (1785 Views)

Background & Aims: Viral hepatitis B is a substantial contributor of dreadful liver disease and hepatocellular carcinoma (HCC) and imposes ponderous burden on the ministry of health around the world. There are no adequate data on the prevalence of Hepatitis-B surface antigen (HBsAg) among Afghan refugees, especially in one of their favorable host countries, Iran. This seroprevalence study aimed to estimate the prevalence rate of HBsAg among Afghan refugees to schedule much more efficient preventive measures.
Materials & Methods: In the current cross-sectional study, data were gathered for a total of 488 Afghan refugees referred to Mehr Medical Diagnostic Laboratory from April 2014 to January 2018. Initial information including age, sex, and education status were extracted. Collected samples from the patients were conducted using the General Biological Corporation (GBC) ELISA Kit to detect seronegative or seropositive HBsAg cases. Following all data were analyzed by SPSS version 16 software.
Results: Sixteen cases with positive HBsAg were detected in 488 Afghan patients referred to the Mehr Laboratory from April 2014 to January 2018. The overall prevalence of HBsAg was calculated 3.3% (2.3% in females and 1% in males). The highest frequencies of HBsAg were associated to the age group of 21 to 30 years with 1.2% and none education level group with 1.8%.
Conclusion: According to the outcome of current study, free vaccination, treatment and screening seropositive individuals in borders will be applied to assist the design and management of preparatory preventive strategies.

Keywords: ELISA, Hepatitis-B surface antigen, Afghan refugees

Full-Text [PDF 366 kb] (541 Downloads)

Type of Study: orginal article | Subject: General

References

1. Blumberg BS. Australia antigen and the biology of hepatitis B. Science 1977;197(4298):17-25. [DOI:10.1126/science.325649] [PMID]

2. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386(10003):1546-55. [DOI:10.1016/S0140-6736(15)61412-X]

3. Chen DS. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. J Hepatol 2009;50(4):805-16. [DOI:10.1016/j.jhep.2009.01.002] [PMID]

4. Ott J, Stevens G, Groeger J, Wiersma S. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30(12):2212-9. [DOI:10.1016/j.vaccine.2011.12.116] [PMID]

5. André F. Hepatitis B epidemiology in Asia, the middle East and Africa. Vaccine 2000;18:S20-S2. [DOI:10.1016/S0264-410X(99)00456-9]

6. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999;12(2):351-66. [DOI:10.1128/CMR.12.2.351] [PMID] [PMCID]

7. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94(2):153-6. [DOI:10.1002/ijc.1440] [PMID]

8. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11(2):97-107. [DOI:10.1046/j.1365-2893.2003.00487.x] [PMID]

9. Liu J, Zhang S, Wang Q, Shen H, Zhang M, Zhang Y, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study. Lancet Infect Dis 2016;16(1):80-6. [DOI:10.1016/S1473-3099(15)00218-2]

10. Helen ts, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010;14(1):1-21. [DOI:10.1016/j.cld.2009.11.009] [PMID]

11. Roberts H, Kruszon-Moran D, Ly KN, Hughes E, Iqbal K, Jiles RB, et al. Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988-2012. Hepatology (Baltimore, Md) 2016;63(2):388-97. [DOI:10.1002/hep.28109] [PMID]

12. Koepke B. Iran's Relations with Afghanistan's National Unity Government. In The Arab World and Iran. Springer; 2016. p. 145-63. [DOI:10.1057/978-1-137-55966-1_9]

13. Manenti A. Health situation in Iran. Med J I.R. Iran 2011;25(1):01-7. [DOI:10.31270/ijame/01/04/2012/02]

14. Todd CS, Ahmadzai M, Atiqzai F, Miller S, Smith JM, Ghazanfar SAS, et al. Seroprevalence and correlates of HIV, syphilis, and hepatitis B and C virus among intrapartum patients in Kabul, Afghanistan. BMC Infect Dis2008;8(1):119. [DOI:10.1186/1471-2334-8-119] [PMID] [PMCID]

15. McMahon BJ. Natural history of chronic hepatitis B-clinical implications.Medscape J Med 2008;10(4):91. [PubMed]

16. Qirbi N, Hall A. Epidemiology of hepatitis B virus infection in the Middle East. East Mediterr Health J 2001;7(6):1034-45. [DOI:10.26719/2001.7.6.1034] [PMID]

17. Kheirabad AK, Jokari EE, Sajjadi M, Gouklani H. Prevalence of Hepatitis B virus between Qeshm Island people in 2013-2014, Iran. Journal of medicine and life 2015;8(Spec Iss 3):173. [PubMed]

18. Salehi-Vaziri M, Sadeghi F, Hashiani AA, Fesharaki MG, Alavian SMJHm. Hepatitis B virus infection in the general population of Iran: an updated systematic review and meta-analysis. Hepat Mon 2016;16(4): e35577. [DOI:10.5812/hepatmon.35577]

19. Gholamreza R, Shahryar S, Abbasali K, Hamidreza J, Abdolvahab M, Khodaberdi K, et al. Seroprevalence of hepatitis B virus and its co-infection with hepatitis D virus and hepatitis C virus in Iranian adult population. Indian Journal of Medical Sciences 2007;61(5):263-8. [DOI:10.4103/0019-5359.32092] [PMID]

20. Alavian SM, Tabatabaei SV, Nourizad S, Mansouri F, Khademi N, Kafi-abad SA, et al. Seroepidemiology of HBV Infection in Kermanshah-West of Iran; a Population Based Study. Jundishapur J Microbiol 2012;5(4):564. [DOI:10.5812/jjm.4156]

21. Alavian SM, Fallahian F, Lankarani KB. Hepatitis B virus infection in Iran; Changing the epidemiology. J Gastrointestin Liver Dis 2010;5(1):51-61. [google scholar]

22. Poorolajal J, Mahmoodi M, Haghdoost A, Majdzadeh R, Nasseri‐Moghaddam S, Ghalichi L, et al. Booster dose vaccination for preventing hepatitis B. Cochrane Database Syst Rev 2016; 2016(6): CD008256. [DOI:10.1002/14651858.CD008256.pub3] [PMID] [PMCID]

23. Zhao S, Xu Z, Lu Y. A mathematical model of hepatitis B virus transmission and its application for vaccination strategy in China. Int J Epidemiol 2000;29(4):744-52. [DOI:10.1093/ije/29.4.744] [PMID]

24. Centers for Disease Control (CDC). Screening for hepatitis B virus infection among refugees arriving in the United States, 1979-1991. MMWR Morb Mortal Wkly Rep 1991;40(45):784. [PubMed]